Irving Levine is a Gastroenterology physician affiliated with NYU Langone Health. OpenAlex indexes 63 publications with 581 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2750 Merrick Rd
Bellmore, NY 117105720
Telephone
516-992-5626Provider last certified this registry record 22 Aug 2024.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year202525 payments
- ABBVIE INC.Program year202520 payments
- Lilly USA, LLCProgram year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
62.1%Aminosalicylate62.1%Mesalamine100%Part D<11 patientsCancer & immunology
37.9%Interleukin-12 Antagonist37.9%Stelara100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Risk of malnutrition increases in the year prior to surgery among patients with inflammatory bowel disease
Therapeutic Advances in Gastroenterology
2025 - GLP-1 Receptor Agonists Confer No Increased Rates of IBD Exacerbation Among Patients With IBD
Inflammatory Bowel Diseases
2024 - S1427 A Single Center Experience of Upadacitinib Treatment for Acute Severe Ulcerative Colitis
The American Journal of Gastroenterology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Harvey Pass, MD
NYU Langone Health
Gareth Morgan, MD
NYU Langone Health
Douglas Kondziolka, MD
NYU Langone Health
Nathan Levin, MD
NYU Langone Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”